Chimeric Therapeutics
Follow
Get notifications in MyBN when activity occurs.
Industry Lists
Public Companies - non WAChimeric Therapeutics is a clinical-stage cell therapy company with a focus on discovering, developing and commercialising novel cell therapies with the most curative potential for patients.
Lists and Charts
Share price
Closing price for the last 90 trading days
Powered by Morningstar ®
Total Shareholder Return as at 31/10/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 1746th | Chimeric Therapeutics | -71% |
1740 WA (and selected non WA) listed companies ranked by
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| th |  | Chimeric Therapeutics | $9.7m |
1334 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Company Activity
| NEW ROLE: Phillip Hains, Chief Financial Officer, Joint Company Secretary, Non Executive Director | 17 Jul 2024 |
| NEW ROLE: Eric Sullivan, Non-Executive Director | 17 Jul 2024 |
| NEWS: Tagged in Chimeric drug declares war on deadly pancreatic cancer | 23 Nov 2023 |
| NEWS: Tagged in Chimeric set to flick switch on clinical leukaemia trial | 20 Nov 2023 |
| NEW ROLE: Jason Litten, | 06 Nov 2023 |
| NEWS: Tagged in Chimeric steps up fight against deadliest brain cancer | 02 Nov 2023 |
| NEWS: Tagged in FDA green-lights Chimeric gastrointestinal cancer drug trials | 31 Oct 2023 |
| NEWS: Tagged in Brain cancer survival hopes lifted in Chimeric trials | 23 Oct 2023 |
| NEWS: Tagged in Chimeric gets US backing for “natural killer” cancer trial | 13 Sep 2023 |
